GOLDING DAVID W
Known title: DirectorCIK: 0001286630
GOLDING DAVID W's purchase track record
GOLDING DAVID W has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/21/2025 | OPCH | $28K | +1.3% | +28.1% | +7.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OPCH | ▲ Buy | Open Market | 1,000 | $28K | 8/21/2025 | View on chart |
| OPCH | ▲ Buy | Grant | 5,034 | $0 | 5/14/2025 | View on chart |
| OPCH | ▲ Buy | Grant | 3,381 | $107K | 5/14/2025 | View on chart |
| OPCH | ▲ Buy | Grant | 6,219 | $0 | 5/15/2024 | View on chart |
| OPCH | ▲ Buy | Grant | 8,427 | $0 | 5/17/2023 | View on chart |
| OPCH | ▲ Buy | Grant | 8,223 | $0 | 5/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
McKesson moves to acquire Option Care Health in $5.8B deal
Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.
McKesson moves to acquire Option Care Health in $5.8B deal. Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.